Multiple Myeloma (relapsed/refractory and front-line) | STOMP

Indication: Relapsed/Refractory and front-line Multiple Myeloma
Title: STOMP: selinexor and Backbone Treatments of Multiple Myeloma Patients
Drug: Selinexor

STOMP is a Phase 1b/2 study evaluating selinexor and low-dose dexamethasone in combination with one of several standard approved therapies, including Revlimid® (lenalidomide), Pomalyst® (pomalidomide), Velcade® (bortezomib), Kyprolis® (carfilzomib), or Darzalex® (daratumumab), in patients with relapsed or refractory multiple myeloma. Additionally, a new arm to this study was added in 2018 to study the combination of selinexor and Revlimid® in newly diagnosed patients with multiple myeloma.

Please visit clinicaltrials.gov for more information about this study

This trial is for selinexor.